Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're not losing weight on Wegovy, or progress has stalled, you are not alone and this is not a sign the treatment has failed you. Semaglutide works differently for different people, and the most useful thing you can do right now is understand which factor is actually at play before drawing any conclusions. This page walks through the main reasons weight loss slows or stalls on Wegovy, what the evidence says, and when it makes sense to speak to your prescriber. These are prescription-only medicines, and any changes to your treatment — dose, timing or approach — need a clinical conversation, not a forum thread. Wegovy (semaglutide) is licensed in the UK for weight management in adults, and a prescriber decides whether it's appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is the most common thing people miss, and it's worth saying plainly: the 0.25mg and 0.5mg doses of Wegovy are not designed to produce meaningful weight loss. They exist to let your body adjust to the medicine and reduce early nausea. The therapeutic work starts at higher doses, typically 1.7mg and 2.4mg, which is why the titration schedule takes several months to reach maintenance. If you started recently and aren't losing weight, the question isn't whether Wegovy works, it's whether you've had enough time at a sufficient dose for it to work.
The STEP 1 trial, published in the New England Journal of Medicine, followed participants at the full 2.4mg dose over 68 weeks and found an average weight reduction of around 15%. That trial didn't produce its headline results at week four on 0.25mg. If you're unsure where you sit on the schedule, that's a question for your prescriber rather than something to adjust yourself.
A plateau at 1.7mg or 2.4mg is different and worth a clinical conversation. If you've been on maintenance dose for three months or more and haven't seen at least 5% change from your starting weight, there are specific things worth reviewing with whoever manages your prescription.
Wegovy reduces appetite reliably for most people, but appetite suppression isn't the same as calorie control, and this distinction matters more than people expect. A smaller appetite means you feel full sooner, but if the foods you eat when you do eat are very calorie-dense, or if your body has adapted its energy expenditure downward (a normal physiological response to weight loss), progress can slow even when the medicine is doing its job.
Protein intake, in particular, deserves attention on treatment. Adequately eating protein at each meal helps preserve lean muscle while losing fat, which in turn supports your resting metabolic rate. Fibre and hydration also play a role in how satisfied you feel between meals. None of this means you need a perfect diet (Wegovy is meant to make changes easier) but the medicine works with lifestyle changes, not instead of them. Practical adjustments that complement treatment are worth understanding before deciding the medicine isn't working.
Strength-based movement is often underestimated. Preserving muscle while losing weight helps avoid the metabolism slowdown that can make a plateau feel permanent. Even moderate resistance activity a couple of times a week can make a meaningful difference over several months of treatment.
Some stalls have nothing to do with dose or diet. Thyroid conditions, insulin resistance, certain medicines and disrupted sleep can all interfere with weight loss even when a GLP-1 medicine is on board. If you have any of these factors in play, a standard Wegovy schedule might need reviewing in the context of your broader health picture.
The NICE appraisal of semaglutide (TA875) recommends stopping treatment if less than 5% weight loss has been achieved after six months on the maintenance dose. That's a clinical threshold, not a judgment, and it points toward reconsidering whether a different approach might serve you better. For some people, that conversation opens a discussion about tirzepatide, which acts on two gut-hormone receptors rather than one and produced larger average results in the SURMOUNT-5 head-to-head trial. Your prescriber is the right person to weigh that up against your individual situation.
A useful starting point if you're uncertain is understanding the typical timeline of weight loss on Wegovy, so you have a realistic benchmark for where you should expect to be at your current stage of treatment.
The decision in front of you is a clinical one, not a Google one. If you're struggling with weight loss on Wegovy and haven't yet had a thorough prescriber review, that's the first step. Changing your dose, switching medicines or stopping treatment should all be done with clinical input, the Patient Information Leaflet and your prescriber are the reference points for anything specific to your regimen.
There's a misconception worth gently laying down here: that struggling on Wegovy means you're not trying hard enough. Biology is more complicated than that, and a medicine that's right for one person at one stage isn't automatically the best fit at every stage. A good prescriber conversation looks at the full picture.
If you're considering starting treatment or reviewing your current prescription, understanding how Wegovy is legally prescribed and supplied in the UK is a sensible place to begin. You can also explore what weight-loss treatment options look like more broadly, or read about semaglutide as the medicine behind Wegovy. For questions about cost and what a private prescription includes, the treatment page sets out what's included in a single transparent price, consultation, clinical review, delivery and aftercare.
If you'd like a clinical perspective on your situation, our prescribers at nume review every consultation the same day it's submitted. Check your eligibility and start a free consultation at our treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.